Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

15th International Conference and Exhibition on Metabolomics & Systems Biology

Kyoto, Japan

Zheng Shuo Jin

Tsinghua University, China

Title: Effect of breast cancer treatment and improve by RSC001 treatment

Biography

Biography: Zheng Shuo Jin

Abstract

Breast cancer is a disease in which malignant cells form in the tissues of the breast. The most common type of breast cancer is ductal carcinoma, which begins in the cells of the ducts. Cancer that begins in the lobes or lobules is called lobular carcinoma and is more often found in both breasts than are other types of breast cancer. Tamoxifen is a type of estrogen- suppressant, in several cases patients treated by Tamoxifen increased the risk rate for breast cancer, therefore, we hope to reduce the complications of endometrial cancer while treating breast cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast. The most common type of breast cancer is ductal carcinoma, which begins in the cells of the ducts. Cancer that begins in the lobes or lobules is called lobular carcinoma and is more often found in both breasts than are other types of breast cancer. Tamoxifen is a type of estrogen- suppressant, in several cases patients treated by Tamoxifen increased the risk rate for breast cancer, therefore, we hope to reduce the complications of endometrial cancer while treating breast cancer.

In the early experiment we used High throughout screening technology select compounds from the drug library and sensitive to gene signature which related to T cell associated genes CXCL9, CXCL10, CXCL11. We discover that MDA-MB-231 human triple negative breast cancer cell treated by RSC001 can induce chemokines also affect expression of STAT genes, classic pathway JAK-STAT will affect chemokines expression, chemokines CXCL10 and CXCL11 will recruit CD8+ T cell for attacking tumor cell. Therefore, though the interconnections between the pathway and chemokines, we need to explore more about RSC001 target point in TNBC cell also the relationship with STAT pathways.